High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
GSE32063_eset.Rd
High-grade serous ovarian cancers are heterogeneous not only in terms of clinical outcome but also at the molecular level. Our aim was to establish a novel risk classification system based on a gene expression signature for predicting overall survival, leading to suggesting novel therapeutic strategies for high-risk patients.In this large-scale cross-platform study of six microarray data sets consisting of 1,054 ovarian cancer patients, we developed a gene expression signature for predicting overall survival by applying elastic net and 10-fold cross-validation to a Japanese data set A (n = 260) and evaluated the signature in five other data sets. Subsequently, we investigated differences in the biological characteristics between high- and low-risk ovarian cancer groups.An elastic net analysis identified a 126-gene expression signature for predicting overall survival in patients with ovarian cancer using the Japanese data set A (multivariate analysis, P = 4 ?? 10(-20)). We validated its predictive ability with five other data sets using multivariate analysis (Tothill's data set, P = 1 ?? 10(-5); Bonome's data set, P = 0.0033; Dressman's data set, P = 0.0016; TCGA data set, P = 0.0027; Japanese data set B, P = 0.021). Through gene ontology and pathway analyses, we identified a significant reduction in expression of immune-response-related genes, especially on the antigen presentation pathway, in high-risk ovarian cancer patients.This risk classification based on the 126-gene expression signature is an accurate predictor of clinical outcome in patients with advanced stage high-grade serous ovarian cancer and has the potential to develop new therapeutic strategies for high-grade serous ovarian cancer patients.
Usage
data( GSE32063_eset )
Format
experimentData(eset):
Experiment data
Experimenter name: Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H et al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res 2012 Mar 1;18(5):1374-85.
Laboratory: Yoshihara, Tanaka 2012
Contact information:
Title: High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
URL:
PMIDs: 22241791
Abstract: A 255 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
Agilent-014850 Whole Human Genome Microarray 4x44K G4112F (Probe Name vers
ion)
platform_shorttitle:
Agilent G4112F
platform_summary:
hgug4112a
platform_manufacturer:
Agilent
platform_distribution:
commercial
platform_accession:
GPL6480
platform_technology:
in situ oligonucleotide
Preprocessing: default
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A1BG A1BG-AS1 ... ZZZ3 (20106 total)
varLabels: probeset gene
varMetadata: labelDescription
Details
assayData: 20106 features, 40 samples
Platform type: hgug4112a
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
records n.max n.start events median 0.95LCL 0.95UCL
40.00 40.00 40.00 22.00 4.44 3.29 NA
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Length Class Mode
40 character character
sample_type:
tumor
40
histological_type:
ser
40
summarygrade:
high low
17 23
summarystage:
late
40
tumorstage:
3 4
31 9
substage:
b c NA's
3 28 9
grade:
2 3
23 17
pltx:
y
40
tax:
y
40
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
210 705 1155 1346 1792 3330
vital_status:
deceased living
22 18
debulking:
optimal suboptimal
19 21
uncurated_author_metadata:
Length Class Mode
40 character character